bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary fig 1 from A Phase II Study of Allogeneic GM-CSF–Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer
Authors: Wu Annie A. , Bever Katherine M. , Ho Won Jin , Fertig Elana J. , Niu Nan , Zheng Lei , Parkinson Rose M. , Durham Jennifer N. , Onners Beth , Ferguson Anna K. , Wilt Cara , Ko Andrew H. , Wang-Gillam Andrea , Laheru Daniel A. , Anders Robert A. , Thompson Elizabeth D. , Sugar Elizabeth A. , Jaffee Elizabeth M. , Le Dung T.
Published: April 2023

Supplementary fig 1 Schematic for defining the immune composition of peripheral blood lymphocytes from Arm A patients using CyTOF.
Supplementary Figure 7 from The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones
Authors: Poschke Isabel C. , Hassel Jessica C. , Rodriguez-Ehrenfried Aaron , Lindner Katharina A.M. , Heras-Murillo Ignacio , Appel Lena M. , Lehmann Johanna , Lövgren Tanja , Wickström Stina L. , Lauenstein Claudia , Roth Jasmin , König Anna-Katharina , Haanen John B.A.G. , van den Berg Joost , Kiessling Rolf , Bergmann Frank , Flossdorf Michael , Strobel Oliver , Offringa Rienk
Published: April 2023

Supplemental Figure 7: Schematic representation of TIL repertoire in different tumor samples from the same patient and the result of ex vivo TIL expansion.
Figure S5 from A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma
Authors: Yang Zijian , LaRiviere Michael J. , Ko Jina , Till Jacob E. , Christensen Theresa , Yee Stephanie S. , Black Taylor A. , Tien Kyle , Lin Andrew , Shen Hanfei , Bhagwat Neha , Herman Daniel , Adallah Andrew , O'Hara Mark H. , Vollmer Charles M. , Katona Bryson W. , Stanger Ben Z. , Issadore David , Carpenter Erica L.
Published: April 2023

Figure S5. Distribution of time to metastasis (TTM) for clinical M0 PDAC patients within our training and test sets. Cross indicates no metastasis observed yet
Figure S4 from A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma
Authors: Yang Zijian , LaRiviere Michael J. , Ko Jina , Till Jacob E. , Christensen Theresa , Yee Stephanie S. , Black Taylor A. , Tien Kyle , Lin Andrew , Shen Hanfei , Bhagwat Neha , Herman Daniel , Adallah Andrew , O'Hara Mark H. , Vollmer Charles M. , Katona Bryson W. , Stanger Ben Z. , Issadore David , Carpenter Erica L.
Published: April 2023

Figure S4. Individual biomarker profiles within the training set. 14 biomarkers' levels by patient group within the training set of 47 subjects. Pancreatic cancer patients (PDAC) relative to Non-Cancer patients (NC). Mann-Whitney test was used to evaluate statistical significance. * means P<0.05, ** means P<0.01, **** means P<0.0001.
Figure S1 from A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma
Authors: Yang Zijian , LaRiviere Michael J. , Ko Jina , Till Jacob E. , Christensen Theresa , Yee Stephanie S. , Black Taylor A. , Tien Kyle , Lin Andrew , Shen Hanfei , Bhagwat Neha , Herman Daniel , Adallah Andrew , O'Hara Mark H. , Vollmer Charles M. , Katona Bryson W. , Stanger Ben Z. , Issadore David , Carpenter Erica L.
Published: April 2023

Figure S1. Sample cohort of this study, which included 204 subjects in total. Workflow shows patient cohorts involved in each classification. * indicated 8 patients repeated in the discovery set and the training set. ** indicated 32 locally advanced patients that were not used in the occult metastases detection as training set did not have locally advanced PDAC patients.
Supplementary Data from Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
Authors: Xu Jianming , Bai Yuxian , Xu Nong , Li Enxiao , Wang Buhai , Wang Jin , Li Xiang , Wang Xin , Yuan Xianglin
Published: April 2023

Supplementary Figures and Tables
Table from Induced Tumor Heterogeneity Reveals Factors Informing Radiation and Immunotherapy Combinations
Authors: Aguilera Todd A. , Elghonaimy Eslam A. , Shehade Hussein , Rafat Marjan , Castellini Laura , Jiang Dadi , Kariolis Mihalis , Koong Albert C. , Le Quynh-Thu , Ellies Lesley G. , Rankin Erinn B. , Graves Edward E. , Giaccia Amato J.
Published: April 2023

supplementary tables 1-4
Supplementary Figure 2 from Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer
Authors: Smyth Lillian M. , Tamura Kenji , Oliveira Mafalda , Ciruelos Eva M. , Mayer Ingrid A. , Sablin Marie-Paule , Biganzoli Laura , Ambrose Helen J. , Ashton Jack , Barnicle Alan , Cashell Des D. , Corcoran Claire , de Bruin Elza C. , Foxley Andrew , Hauser Joana , Lindemann Justin P.O. , Maudsley Rhiannon , McEwen Robert , Moschetta Michele , Pass Martin , Rowlands Vicky , Schiavon Gaia , Banerji Udai , Scaltriti Maurizio , Taylor Barry S. , Chandarlapaty Sarat , Baselga José , Hyman David M.
Published: April 2023

Supplementary Figure 2. PFS Association With {greater than or equal to}50% Decrease from Baseline in AKT1E17K at Cycle 2 Day 1 in ctDNA
Supplementary figure 4: PFS and OS by ajcc8 from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Authors: Weiss Jared , Sheth Siddharth , Deal Allision M. , Grilley Olson Juneko E. , Patel Samip , Hackman Trevor G. , Blumberg Jeffrey M. , Galloway Thomas J. , Patel Shetal , Zanation Adam M. , Shen Colette J. , Hayes D. Neil , Hilliard Christopher , Mehra Ranee , McKinnon Karen P. , Wang Hsing-Hui , Weissler Mark Christian , Bauman Jessica R. , Chera Bhishamjit S. , Vincent Benjamin G.
Published: April 2023

PFS and OS by AJCC 8
Supplementary Figure 2: T cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Authors: Weiss Jared , Sheth Siddharth , Deal Allision M. , Grilley Olson Juneko E. , Patel Samip , Hackman Trevor G. , Blumberg Jeffrey M. , Galloway Thomas J. , Patel Shetal , Zanation Adam M. , Shen Colette J. , Hayes D. Neil , Hilliard Christopher , Mehra Ranee , McKinnon Karen P. , Wang Hsing-Hui , Weissler Mark Christian , Bauman Jessica R. , Chera Bhishamjit S. , Vincent Benjamin G.
Published: April 2023

T cell gating
Supplementary Methods from Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition
Authors: Truong Amanda , Yoo Jae Hyuk , Scherzer Michael T. , Sanchez John Michael S. , Dale Kali J. , Kinsey Conan G. , Richards Jackson R. , Shin Donghan , Ghazi Phaedra C. , Onken Michael D. , Blumer Kendall J. , Odelberg Shannon J. , McMahon Martin
Published: April 2023

Supplementary Materials and Methods
Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
Authors: Weiss Jared , Sheth Siddharth , Deal Allision M. , Grilley Olson Juneko E. , Patel Samip , Hackman Trevor G. , Blumberg Jeffrey M. , Galloway Thomas J. , Patel Shetal , Zanation Adam M. , Shen Colette J. , Hayes D. Neil , Hilliard Christopher , Mehra Ranee , McKinnon Karen P. , Wang Hsing-Hui , Weissler Mark Christian , Bauman Jessica R. , Chera Bhishamjit S. , Vincent Benjamin G.
Published: April 2023

Supplementary figure legends
Figure S6 from Chloroquine Sensitizes GNAQ/11-mutated Melanoma to MEK1/2 Inhibition
Authors: Truong Amanda , Yoo Jae Hyuk , Scherzer Michael T. , Sanchez John Michael S. , Dale Kali J. , Kinsey Conan G. , Richards Jackson R. , Shin Donghan , Ghazi Phaedra C. , Onken Michael D. , Blumer Kendall J. , Odelberg Shannon J. , McMahon Martin
Published: April 2023

Trametinib in combination with macropinocytosis or mitophagy inhibition
Supplementary fig 5 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Authors: Wu Christina , Williams Terence M. , Robb Ryan , Webb Amy , Wei Lai , Chen Wei , Mikhail Sameh , Ciombor Kristen K. , Cardin Dana B. , Timmers Cynthia , Krishna Somashekar G. , Arnold Mark , Harzman Alan , Abdel-Misih Sherif , Roychowdhury Sameek , Bekaii-Saab Tanios , Wuthrick Evan
Published: April 2023

Supplementary fig 5 Degree of Reduction (%) in Tumor pERK Levels From Baseline to After Trametinib Monotherapy and Correlation With pCR
Supplementary fig 2 from Phase I Trial of Trametinib with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer
Authors: Wu Christina , Williams Terence M. , Robb Ryan , Webb Amy , Wei Lai , Chen Wei , Mikhail Sameh , Ciombor Kristen K. , Cardin Dana B. , Timmers Cynthia , Krishna Somashekar G. , Arnold Mark , Harzman Alan , Abdel-Misih Sherif , Roychowdhury Sameek , Bekaii-Saab Tanios , Wuthrick Evan
Published: April 2023

Supplementary fig 2 Schema for trial design
Supplementary Tables S1-S10. Supplementary Figures S1-S5. from Prognostic Significance of Immune Cell Populations Identified by Machine Learning in Colorectal Cancer Using Routine Hematoxylin and Eosin–Stained Sections
Authors: Väyrynen Juha P. , Lau Mai Chan , Haruki Koichiro , Väyrynen Sara A. , Dias Costa Andressa , Borowsky Jennifer , Zhao Melissa , Fujiyoshi Kenji , Arima Kota , Twombly Tyler S. , Kishikawa Junko , Gu Simeng , Aminmozaffari Saina , Shi Shanshan , Baba Yoshifumi , Akimoto Naohiko , Ugai Tomotaka , Da Silva Annacarolina , Song Mingyang , Wu Kana , Chan Andrew T. , Nishihara Reiko , Fuchs Charles S. , Meyerhardt Jeffrey A. , Giannakis Marios , Ogino Shuji , Nowak Jonathan A.
Published: April 2023

Table S1. Analyses of MSI, DNA methylation, KRAS, BRAF, and PIK3CA mutations, and neoantigen load. Table S2. Clinical and pathological characteristics of colorectal cancer cases according to tumor stromal immune cell densities in TCGA dataset. Table S3. Steps of immune cell detection and quantification and tissue category classification from images of H&E stained sections using QuPath. Table S4. Statistical methods for survival analysis. Table S5. Immune cell densities in tumor intraepithelial and stromal regions and colorectal cancer-specific survival with inverse probability weighting (IPW). Table S6. Densities of stromal lymphocytes, plasma cells, and eosinophils and patient survival in strata of MSI status with inverse probability weighting (IPW). Table S7. Comparison of the prognostic power of immune cell densities in colorectal cancer-specific survival analyses. Table S8. Combination of spatial G-cross measurement and density measurements of lymphocytes, plasma cells, neutrophils, and eosinophils in relation to colorectal cancer-specific survival. Table S9. Densities of intraepithelial and stromal immune cells and patient survival in TCGA dataset. Table S10. Tumor:Immune cell G-cross function area under the curve and patient survival in TCGA dataset. Figure S1. Reproducibility of the immune cell counting. Figure S2. Boxplots of the densities of intraepithelial and stromal lymphocytes, plasma cells, neutrophils, and eosinophils across 10 TMAs. Figure S3. UMAP analysis of colorectal cancer cases according to intraepithelial and stromal densities of lymphocytes, plasma cells, neutrophils, and eosinophils. Figure S4. Relationships of intraepithelial and stromal immune cell densities with LINE-1 methylation level, BRAF mutation, KRAS mutation, and PIK3CA mutation. Figure S5. Inverse probability weighting-adjusted Kaplan-Meier curves of colorectal cancer-specific survival according to ordinal categories (C1-C4) of intraepithelial lymphocyte (A), plasma cell (B), neutrophil (C), and eosinophil (D) densities.
Supplementary Tables from Cancer Antigen Discovery Is Enabled by RNA Sequencing of Highly Purified Malignant and Nonmalignant Cells
Authors: Scurr Martin J. , Greenshields-Watson Alex , Campbell Emma , Somerville Michelle S. , Chen Yuan , Hulin-Curtis Sarah L. , Burnell Stephanie E.A. , Davies James A. , Davies Michael M. , Hargest Rachel , Phillips Simon , Christian Adam D. , Ashelford Kevin E. , Andrews Robert , Parker Alan L. , Stanton Richard J. , Gallimore Awen , Godkin Andrew
Published: April 2023

Supplementary Tables 1-9
Figure S1 from DNA Methylation Profiling Identifies Distinct Clusters in Angiosarcomas
Authors: Weidema Marije E. , van de Geer Ellen , Koelsche Christian , Desar Ingrid M.E. , Kemmeren Patrick , Hillebrandt-Roeffen Melissa H.S. , Ho Vincent K.Y. , van der Graaf Winette T.A. , Versleijen-Jonkers Yvonne M.H. , von Deimling Andreas , Flucke Uta E.
Published: April 2023

Methylation-specific PCR MGMT
Supplementary Data from Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma
Authors: Chong Wan Qin , Lim Chwee Ming , Sinha Arvind Kumar , Tan Chee Seng , Chan Gloria Hui Jia , Huang Yiqing , Kumarakulasinghe Nesaretnam Barr , Sundar Raghav , Jeyasekharan Anand D. , Loh Woei Shyang , Tay Joshua K. , Yadav Kritika , Wang Lingzhi , Wong Andrea L. , Kong Li Ren , Soo Ross Andrew , Lau Jieying Amelia , Soon Yu Yang , Goh Robby Miguel , Ho Francis Cho Hao , Chong Siew Meng , Lee Soo Chin , Loh Kwok Seng , Tai Bee Choo , Lim Yaw Chyn , Goh Boon Cher
Published: April 2023

Supplementary methods and supplementary tables
Supplemental Figure SF-13 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Expression of Melanoma Marker Genes Portends Unfavorable RFS and OS in Group A but not Group B. Expression of Apoptotic Marker Genes Portends Favorable RFS and OS in Group A but not Group B.
Figure S8 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Authors: Balachander Srividya B. , Criscione Steven W. , Byth Kate F. , Cidado Justin , Adam Ammar , Lewis Paula , Macintyre Terry , Wen Shenghua , Lawson Deborah , Burke Kathleen , Lubinski Tristan , Tyner Jeffrey W. , Kurtz Stephen E. , McWeeney Shannon K. , Varnes Jeffrey , Diebold R. Bruce , Gero Thomas , Ioannidis Stephanos , Hennessy Edward J. , McCoull William , Saeh Jamal C. , Tabatabai Areya , Tavana Omid , Su Nancy , Schuller Alwin , Garnett Mathew J. , Jaaks Patricia , Coker Elizabeth A. , Gregory Gareth P. , Newbold Andrea , Johnstone Ricky W. , Gangl Eric , Wild Martin , Zinda Michael , Secrist J. Paul , Davies Barry R. , Fawell Stephen E. , Gibbons Francis D.
Published: April 2023

Figure S8
Figure S7 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Authors: Balachander Srividya B. , Criscione Steven W. , Byth Kate F. , Cidado Justin , Adam Ammar , Lewis Paula , Macintyre Terry , Wen Shenghua , Lawson Deborah , Burke Kathleen , Lubinski Tristan , Tyner Jeffrey W. , Kurtz Stephen E. , McWeeney Shannon K. , Varnes Jeffrey , Diebold R. Bruce , Gero Thomas , Ioannidis Stephanos , Hennessy Edward J. , McCoull William , Saeh Jamal C. , Tabatabai Areya , Tavana Omid , Su Nancy , Schuller Alwin , Garnett Mathew J. , Jaaks Patricia , Coker Elizabeth A. , Gregory Gareth P. , Newbold Andrea , Johnstone Ricky W. , Gangl Eric , Wild Martin , Zinda Michael , Secrist J. Paul , Davies Barry R. , Fawell Stephen E. , Gibbons Francis D.
Published: April 2023

Figure S7
Figure S5 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Authors: Balachander Srividya B. , Criscione Steven W. , Byth Kate F. , Cidado Justin , Adam Ammar , Lewis Paula , Macintyre Terry , Wen Shenghua , Lawson Deborah , Burke Kathleen , Lubinski Tristan , Tyner Jeffrey W. , Kurtz Stephen E. , McWeeney Shannon K. , Varnes Jeffrey , Diebold R. Bruce , Gero Thomas , Ioannidis Stephanos , Hennessy Edward J. , McCoull William , Saeh Jamal C. , Tabatabai Areya , Tavana Omid , Su Nancy , Schuller Alwin , Garnett Mathew J. , Jaaks Patricia , Coker Elizabeth A. , Gregory Gareth P. , Newbold Andrea , Johnstone Ricky W. , Gangl Eric , Wild Martin , Zinda Michael , Secrist J. Paul , Davies Barry R. , Fawell Stephen E. , Gibbons Francis D.
Published: April 2023

Figure S5
Supplemental Figure SF-07 from Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2
Authors: Yang Richard K. , Kuznetsov Igor B. , Ranheim Erik A. , Wei Jun S. , Sindiri Sivasish , Gryder Berkley E. , Gangalapudi Vineela , Song Young K. , Patel Viharkumar , Hank Jacquelyn A. , Zuleger Cindy , Erbe Amy K. , Morris Zachary S. , Quale Renae , Kim KyungMann , Albertini Mark R. , Khan Javed , Sondel Paul M.
Published: April 2023

Toll-Like Receptors Prognosticate Favorable Survival in Group A, But Not Group B
Figure S3 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Authors: Balachander Srividya B. , Criscione Steven W. , Byth Kate F. , Cidado Justin , Adam Ammar , Lewis Paula , Macintyre Terry , Wen Shenghua , Lawson Deborah , Burke Kathleen , Lubinski Tristan , Tyner Jeffrey W. , Kurtz Stephen E. , McWeeney Shannon K. , Varnes Jeffrey , Diebold R. Bruce , Gero Thomas , Ioannidis Stephanos , Hennessy Edward J. , McCoull William , Saeh Jamal C. , Tabatabai Areya , Tavana Omid , Su Nancy , Schuller Alwin , Garnett Mathew J. , Jaaks Patricia , Coker Elizabeth A. , Gregory Gareth P. , Newbold Andrea , Johnstone Ricky W. , Gangl Eric , Wild Martin , Zinda Michael , Secrist J. Paul , Davies Barry R. , Fawell Stephen E. , Gibbons Francis D.
Published: April 2023

Figure S3
Figure S10 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia
Authors: Balachander Srividya B. , Criscione Steven W. , Byth Kate F. , Cidado Justin , Adam Ammar , Lewis Paula , Macintyre Terry , Wen Shenghua , Lawson Deborah , Burke Kathleen , Lubinski Tristan , Tyner Jeffrey W. , Kurtz Stephen E. , McWeeney Shannon K. , Varnes Jeffrey , Diebold R. Bruce , Gero Thomas , Ioannidis Stephanos , Hennessy Edward J. , McCoull William , Saeh Jamal C. , Tabatabai Areya , Tavana Omid , Su Nancy , Schuller Alwin , Garnett Mathew J. , Jaaks Patricia , Coker Elizabeth A. , Gregory Gareth P. , Newbold Andrea , Johnstone Ricky W. , Gangl Eric , Wild Martin , Zinda Michael , Secrist J. Paul , Davies Barry R. , Fawell Stephen E. , Gibbons Francis D.
Published: April 2023

Figure S10
Supplementary Figure Captions from Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor–Positive Breast Cancers
Authors: Pesch Andrea M. , Hirsh Nicole H. , Chandler Benjamin C. , Michmerhuizen Anna R. , Ritter Cassandra L. , Androsiglio Marlie P. , Wilder-Romans Kari , Liu Meilan , Gersch Christina L. , Larios José M. , Pierce Lori J. , Rae James M. , Speers Corey W.
Published: April 2023

Captions for Supplementary Figures 1-9
Supplementary Data from Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor–Positive Breast Cancers
Authors: Pesch Andrea M. , Hirsh Nicole H. , Chandler Benjamin C. , Michmerhuizen Anna R. , Ritter Cassandra L. , Androsiglio Marlie P. , Wilder-Romans Kari , Liu Meilan , Gersch Christina L. , Larios José M. , Pierce Lori J. , Rae James M. , Speers Corey W.
Published: April 2023

Supplementary Figures 1-9 and Supplementary Tables 1-6
Supplementary Methods from Low-Dose Hsp90 Inhibitor Selectively Radiosensitizes HNSCC and Pancreatic Xenografts
Authors: Mehta Ranjit K. , Pal Sanjima , Kondapi Koushik , Sitto Merna , Dewar Cuyler , Devasia Theresa , Schipper Matthew J. , Thomas Dafydd G. , Basrur Venkatesha , Pai Manjunath P. , Morishima Yoshihiro , Osawa Yoichi , Pratt William B. , Lawrence Theodore S. , Nyati Mukesh K.
Published: April 2023

Supplementary Methods
Supplement 6 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
Authors: Fenk Roland , Giagounidis Aristoteles , Goldschmidt Hartmut , Heinsch Michael , Rummel Mathias , Kroger Nicolaus , Boquoi Amelie , Lopez David , Gerrlich Celina , Baier Julia , Liesenjohann Svenja , Hauck Katarzyna , Savickaite Ingrida , Mai Elias K. , Aul Carlo , Strapatsas Judith , Dienst Ariane , Kondakci Mustafa , Haas Rainer , Kobbe Guido
Published: April 2023

AE incidence and severity
Supplement 3 from Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation
Authors: Fenk Roland , Giagounidis Aristoteles , Goldschmidt Hartmut , Heinsch Michael , Rummel Mathias , Kroger Nicolaus , Boquoi Amelie , Lopez David , Gerrlich Celina , Baier Julia , Liesenjohann Svenja , Hauck Katarzyna , Savickaite Ingrida , Mai Elias K. , Aul Carlo , Strapatsas Judith , Dienst Ariane , Kondakci Mustafa , Haas Rainer , Kobbe Guido
Published: April 2023

Exposure and remissions
Supplementary Table 1 from A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer
Authors: Aggarwal Rahul R. , Schweizer Michael T. , Nanus David M. , Pantuck Allan J. , Heath Elisabeth I. , Campeau Eric , Attwell Sarah , Norek Karen , Snyder Margo , Bauman Lisa , Lakhotia Sanjay , Feng Felix Y. , Small Eric J. , Abida Wassim , Alumkal Joshi J.
Published: April 2023

Supplementary Table 1
Supplementary Table 2 from Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer
Authors: Agarwal Neeraj , Nussenzveig Roberto , Hahn Andrew W. , Hoffman John M. , Morton Kathryn , Gupta Sumati , Batten Julia , Thorley Jared , Hawks Josiah , Santos Victor Sacristan , Nachaegari Gayatri , Wang Xuechen , Boucher Kenneth , Haaland Benjamin , Maughan Benjamin L.
Published: April 2023

Time to nadir for BMMs and PSA.
Table S2 from Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers
Authors: Klein Oliver , Kee Damien , Markman Ben , Michael Michael , Underhill Craig , Carlino Matteo S. , Jackett Louise , Lum Caroline , Scott Clare , Nagrial Adnan , Behren Andreas , So Jane Y. , Palmer Jodie , Cebon Jonathan
Published: April 2023

Best response according to histological grade
Figuse S1 from Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial
Authors: Li Xi , Zhang Li , Jiang Da , Wang Yan , Zang Aimin , Ding Cuimin , Zhao Min , Su Wuyun , Zhang Yan , Zhong Diansheng , Wu Jin , Zhang Cuiying , An Guangyu , Hu Xingsheng , Cheng Gang , Wang Huaqing , Li Yongqun , He Xiaohui , Liu Junli , Liang Li , Ding Lieming , Mao Li , Zhang Shucai
Published: April 2023

Kaplan-Meier estimate of overall survival
Supplemental Table 2 from A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Authors: Postow Michael A. , Knox Susan J. , Goldman Debra A. , Elhanati Yuval , Mavinkurve Vikram , Wong Phillip , Halpenny Darragh , Reddy Sunil K. , Vado Kenya , McCabe Danielle , Ramirez Kristen Aufiero , Macri Mary , Schwarzenberger Paul , Ricciardi Toni , Ryan Aileen , Venhaus Ralph , Momtaz Parisa , Shoushtari Alexander N. , Callahan Margaret K. , Chapman Paul B. , Wolchok Jedd D. , Subrahmanyam Priyanka B. , Maecker Holden T. , Panageas Katherine S. , Barker Christopher A.
Published: April 2023

Per patient description of site of RT, response in irradiated volume, and baseline sum of target irradiated volume
Table S1 from Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis
Authors: Chu Jenny E. , Johnson Benny , Kugathasan Laveniya , Morris Van K. , Raghav Kanwal , Swanson Lucas , Lim Howard J. , Renouf Daniel J. , Gill Sharlene , Wolber Robert , Karsan Aly , Kopetz Scott , Schaeffer David F. , Loree Jonathan M.
Published: April 2023

Prevalence of BRAFV600E mutated colorectal cancer by IHC testing within VCH population-based cohort.
Figure S3 from Population-based Screening for BRAFV600E in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis
Authors: Chu Jenny E. , Johnson Benny , Kugathasan Laveniya , Morris Van K. , Raghav Kanwal , Swanson Lucas , Lim Howard J. , Renouf Daniel J. , Gill Sharlene , Wolber Robert , Karsan Aly , Kopetz Scott , Schaeffer David F. , Loree Jonathan M.
Published: April 2023

Kaplan-Meier estimation of overall survival of mCRC patients with BRAFV600E mutations detected by (A) IHC (BRAFIHC) and (B) NGS (BRAFNGS) demonstrates no survival difference between those with dMMR versus pMMR for BRAFIHC and BRAFNGS within individual groups.
Supplemental Figure 3b from Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia
Authors: Danilov Alexey V. , Herbaux Charles , Walter Harriet S. , Hillmen Peter , Rule Simon A. , Kio Ebenezer A. , Karlin Lionel , Dyer Martin J.S. , Mitra Siddhartha S. , Yi Ping Cheng , Humeniuk Rita , Huang Xi , Zhou Ziqian , Bhargava Pankaj , Jürgensmeier Juliane M. , Fegan Christopher D.
Published: April 2023

Supplemental Figure 3. Mean (SD) TIRA plasma concentration. Cycle 1 Day 8 data are shown in patients receiving TIRA monotherapy with A) TIRA/IDELA, and B) TIRA/ENTO*
Supplementary Data from Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study
Authors: Xing Ligang , Pan Yueyin , Shi Yuankai , Shu Yongqian , Feng Jifeng , Li Wei , Cao Lejie , Wang Lifeng , Gu Wei , Song Yong , Xing Puyuan , Liu Yutao , Gao Wen , Cui Jiuwei , Hu Nana , Li Rutian , Bao Hua , Shao Yang , Yu Jinming
Published: April 2023

Supplementary Figure 2
Supplementary Data from Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study
Authors: Xing Ligang , Pan Yueyin , Shi Yuankai , Shu Yongqian , Feng Jifeng , Li Wei , Cao Lejie , Wang Lifeng , Gu Wei , Song Yong , Xing Puyuan , Liu Yutao , Gao Wen , Cui Jiuwei , Hu Nana , Li Rutian , Bao Hua , Shao Yang , Yu Jinming
Published: April 2023

Supplementary Figure 3
Supplementary Table S2 from A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
Authors: Tolaney Sara M. , Sahebjam Solmaz , Le Rhun Emilie , Bachelot Thomas , Kabos Peter , Awada Ahmad , Yardley Denise , Chan Arlene , Conte Pierfranco , Diéras Véronique , Lin Nancy U. , Bear Melissa , Chapman Sonya C. , Yang Zhengyu , Chen Yanyun , Anders Carey K.
Published: April 2023

Plasma concentrations of abemaciclib after a single dose (C1D1) or at steady state, following a twice-daily dosing schedule of abemaciclib.
Supplementary Table S1 from A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer
Authors: Tolaney Sara M. , Sahebjam Solmaz , Le Rhun Emilie , Bachelot Thomas , Kabos Peter , Awada Ahmad , Yardley Denise , Chan Arlene , Conte Pierfranco , Diéras Véronique , Lin Nancy U. , Bear Melissa , Chapman Sonya C. , Yang Zhengyu , Chen Yanyun , Anders Carey K.
Published: April 2023

Prior and concomitant therapies in patients from cohort A (HR+, HER2-) with intracranial clinical benefit.
Supplementary Table S1 from Radiation-induced Adaptive Response: New Potential for Cancer Treatment
Authors: Coleman C. Norman , Eke Iris , Makinde Adeola Y. , Chopra Sunita , Demaria Sandra , Formenti Silvia C. , Martello Shannon , Bylicky Michelle , Mitchell James B. , Aryankalayil Molykutty J.
Published: April 2023

Metabolic data from PC3 cells 6h, 24h, and 48h after SD or MF radiation. Samples were sent to Metabolon for processing. Results indicate decrease in glycolysis intermediates in SD sample at 6h. No significant changes to TCA cycle intermediates. No significant changes to ATP at any time points measured.
Supplementary fig 4 from PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer
Authors: Ahmed Fahad Shabbir , Gaule Patricia , McGuire John , Patel Katir , Blenman Kim , Pusztai Lajos , Rimm David L.
Published: April 2023

expression compartment comparisons
Supplementary fig 2 from PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer
Authors: Ahmed Fahad Shabbir , Gaule Patricia , McGuire John , Patel Katir , Blenman Kim , Pusztai Lajos , Rimm David L.
Published: April 2023

methods table describing batches and antibodies
Supplementary Table 5 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

Supplementary Table 5
Supplementary Figure 9 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

Explorative analyses of overall survival according to standardized KELIM terciles (upper vs intermediate + lower) and disease risk-group adjusted from Oza et al. Med.: Median; std: standardized; NR: not reached; 95% CI: 95% confidence interval; P: Log-rank test.
Supplementary Figure 4 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

Receiver Operating Characteristics curve regarding Complete interval debulking surgery (Yes vs No) according to KELIM. Selection of the best predictive KELIM cut-off using Youden index.
Supplementary Figure 3 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

Visual predictive checks. Purple areas represent the 95% confidence intervals of the 10th, 50th, and 90th percentiles of simulated data. Red lines represent the median (solid line), and the 10th and 90th percentiles (dashed lines) of the observations.
Supplementary Information from Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas
Authors: Scheetz Lindsay , Kadiyala Padma , Sun Xiaoqi , Son Sejin , Hassani Najafabadi Alireza , Aikins Marisa , Lowenstein Pedro R. , Schwendeman Anna , Castro Maria G. , Moon James J.
Published: April 2023

Supplementary Table 1 Supplementary Figures 1-4
Supplementary Figure 2 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

Goodness-of-fit plots. Predicted versus observed CA-125 concentrations are shown for the population (left panel) and for individuals (right panel). Black line: identity line.
Supplementary Figure 1 from CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Authors: You Benoit , Robelin Patrick , Tod Michel , Louvet Christophe , Lotz Jean-Pierre , Abadie-Lacourtoisie Sophie , Fabbro Michel , Desauw Christophe , Bonichon-Lamichhane Nathalie , Kurtz Jean-Emmanuel , Follana Philippe , Leheurteur Marianne , Piano Francesco Del , Ferron Gwénael , De Rauglaudre Gaëtan , Ray-Coquard Isabelle , Combe Pierre , Chevalier-Place Annick , Joly Florence , Leary Alexandra , Pujade-Lauraine Eric , Freyer Gilles , Colomban Olivier
Published: April 2023

Flowchart of the study. IDS: Interval debulking surgery; PFS: progression-free survival; OS: overall survival.
Table S4 from Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance
Authors: Smalley Inna , Law Vincent , Wyatt Clayton , Evernden Brittany , Fang Bin , Koomen John M. , Welsh Eric A. , Macaulay Robert J.B. , Forsyth Peter A. , Smalley Keiran S.M.
Published: April 2023

The fold changes in gene expression between the vemurafenib treated and vehicle treated cells for each cell culture condition
Supplementary Tables S1 and S2 from How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma
Authors: Cohen Adam D. , Raje Noopur , Fowler Jessica A. , Mezzi Khalid , Scott Emma C. , Dhodapkar Madhav V.
Published: April 2023

Table S1 shows ongoing vaccine trials with unpublished data for multiple myeloma disease stages with lower tumor burden/immunosuppression. Table S2 shows checkpoint inhibitor-based trials in patients with relapsed and/or refractory multiple myeloma with unpublished data.
Table S3 from Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance
Authors: Smalley Inna , Law Vincent , Wyatt Clayton , Evernden Brittany , Fang Bin , Koomen John M. , Welsh Eric A. , Macaulay Robert J.B. , Forsyth Peter A. , Smalley Keiran S.M.
Published: April 2023

Poor responder LMM CSF vs no LMM CSF significantly altered proteins and their IPA analysis
Supplementary Tables and Figures from A Novel Splice Variant of HYAL-4 Drives Malignant Transformation and Predicts Outcome in Patients with Bladder Cancer
Authors: Lokeshwar Vinata B. , Morera Daley S. , Hasanali Sarrah L. , Yates Travis J. , Hupe Marie C. , Knapp Judith , Lokeshwar Soum D. , Wang Jiaojiao , Hennig Martin J.P. , Baskar Rohitha , Escudero Diogo O. , Racine Ronny R. , Dhir Neetika , Jordan Andre R. , Hoye Kelly , Azih Ijeoma , Manoharan Murugesan , Klaassen Zachary , Kavuri Sravan , Lopez Luis E. , Ghosh Santu , Lokeshwar Bal L.
Published: April 2023

Four Supplementary Figures and Seven Supplementary Tables
Table S1 from Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance
Authors: Smalley Inna , Law Vincent , Wyatt Clayton , Evernden Brittany , Fang Bin , Koomen John M. , Welsh Eric A. , Macaulay Robert J.B. , Forsyth Peter A. , Smalley Keiran S.M.
Published: April 2023

TMT Batch Setup
Supplementary Table S2 from Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study
Authors: Harrington Kevin J. , Kong Anthony , Mach Nicolas , Chesney Jason A. , Fernandez Beatriz Castelo , Rischin Danny , Cohen Ezra E.W. , Radcliffe Hoi-Shen , Gumuscu Burak , Cheng Jonathan , Snyder Wendy , Siu Lillian L.
Published: April 2023

Lesion-level best overall response in injected lesions vs. uninjected lesions
Figure S3 from Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)
Authors: Kawazoe Akihito , Kuboki Yasutoshi , Shinozaki Eiji , Hara Hiroki , Nishina Tomohiro , Komatsu Yoshito , Yuki Satoshi , Wakabayashi Masashi , Nomura Shogo , Sato Akihiro , Kuwata Takeshi , Kawazu Masahito , Mano Hiroyuki , Togashi Yosuke , Nishikawa Hiroyoshi , Yoshino Takayuki
Published: April 2023

Figure S3. (A) Kaplan-Meier plots of progression-free survival in cohort A. (B) Progression-free survival in cohort B. (C) Overall survival in cohort A. (D) Overall survival in cohort B.
Supplementary Table S7 from A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Authors: Zeidan Amer M. , Ridinger Maya , Lin Tara L. , Becker Pamela S. , Schiller Gary J. , Patel Prapti A. , Spira Alexander I. , Tsai Michaela L. , Samuëlsz Errin , Silberman Sandra L. , Erlander Mark , Wang Eunice S.
Published: April 2023

Detailed list of variants identified by targeted-NGS
Figure S2 from Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)
Authors: Kawazoe Akihito , Kuboki Yasutoshi , Shinozaki Eiji , Hara Hiroki , Nishina Tomohiro , Komatsu Yoshito , Yuki Satoshi , Wakabayashi Masashi , Nomura Shogo , Sato Akihiro , Kuwata Takeshi , Kawazu Masahito , Mano Hiroyuki , Togashi Yosuke , Nishikawa Hiroyoshi , Yoshino Takayuki
Published: April 2023

Figure S2. Computed tomography during the study treatment of the 4 patients with objective response in cohort B
Supplemental Figure 2 from Multiplexed Evaluation of Microdosed Antineoplastic Agents In Situ in the Tumor Microenvironment of Patients with Soft Tissue Sarcoma
Authors: Gundle Kenneth R. , Deutsch Gary B. , Goodman Howard J. , Pollack Seth M. , Thompson Matthew J. , Davis Jessica L. , Lee Mee-Young , Ramirez Daniel C. , Kerwin William , Bertout Jessica A. , Grenley Marc O. , Sottero Kimberly H.W. , Beirne Emily , Frazier Jason , Dey Joyoti , Ellison Micah , Klinghoffer Richard A. , Maki Robert G.
Published: April 2023

Representative images of tumors from patients who received radiation treatment.
Figure S1 from A Four-Chemokine Signature Is Associated with a T-cell–Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer
Authors: Romero Joan M. , Grünwald Barbara , Jang Gun-Ho , Bavi Prashant P. , Jhaveri Aaditeya , Masoomian Mehdi , Fischer Sandra E. , Zhang Amy , Denroche Robert E. , Lungu Ilinca M. , De Luca Angela , Bartlett John M.S. , Xu Jing , Li Niandong , Dhaliwal Sharon , Liang Sheng-Ben , Chadwick Dianne , Vyas Foram , Bronsert Peter , Khokha Rama , McGaha Tracy L. , Notta Faiyaz , Ohashi Pamela S. , Done Susan J. , O'Kane Grainne M. , Wilson Julie M. , Knox Jennifer J. , Connor Ashton , Wang Yifan , Zogopoulos George , Gallinger Steven
Published: April 2023

Supplementary Figure 1: Overview of methodology and cohorts
Figure S6 from Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase–Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type
Authors: Ji Jennifer X. , Cochrane Dawn R. , Tessier-Cloutier Basile , Chen Shary Yutin , Ho Germain , Pathak Khyatiben V. , Alcazar Isabel N. , Farnell David , Leung Samuel , Cheng Angela , Chow Christine , Colborne Shane , Negri Gian Luca , Kommoss Friedrich , Karnezis Anthony , Morin Gregg B. , McAlpine Jessica N. , Gilks C. Blake , Weissman Bernard E. , Trent Jeffrey M. , Hoang Lynn , Pirrotte Patrick , Wang Yemin , Huntsman David G.
Published: April 2023

IC50 curves for ADI-PEG20 in ovarian cancer cell lines. A, ASS1-deficient ovarian cancer cell lines and B, ASS1-proficient ovarian cancer cell lines.
Supplementary Data from Molecular Engineering of Ultrasmall Silica Nanoparticle–Drug Conjugates as Lung Cancer Therapeutics
Authors: Madajewski Brian , Chen Feng , Yoo Barney , Turker Melik Z. , Ma Kai , Zhang Li , Chen Pei-Ming , Juthani Rupa , Aragon-Sanabria Virginia , Gonen Mithat , Rudin Charles M. , Wiesner Ulrich , Bradbury Michelle S. , Brennan Cameron
Published: April 2023

All supplemental data
Supplementary Data 5 from Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma
Authors: Bachet Jean-Baptiste , Blons Hélène , Hammel Pascal , Hariry Iman El , Portales Fabienne , Mineur Laurent , Metges Jean-Philippe , Mulot Claire , Bourreau Camille , Cain Jason , Cros Jérôme , Laurent-Puig Pierre
Published: April 2023

Description of patients' characteristics according to tertiles of ctDNA VAF frequency at baseline
Supplementary Data 3 from Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma
Authors: Bachet Jean-Baptiste , Blons Hélène , Hammel Pascal , Hariry Iman El , Portales Fabienne , Mineur Laurent , Metges Jean-Philippe , Mulot Claire , Bourreau Camille , Cain Jason , Cros Jérôme , Laurent-Puig Pierre
Published: April 2023

Patients characteristics at baseline according the presence or not of ctDNA
Supplementary figures and tables from Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment
Authors: Chen Runzhe , Lee Won-Chul , Fujimoto Junya , Li Jun , Hu Xin , Mehran Reza , Rice David , Swisher Stephen G. , Sepesi Boris , Tran Hai T. , Chow Chi-Wan , Little Latasha D. , Gumbs Curtis , Haymaker Cara , Heymach John V. , Wistuba Ignacio I. , Lee J. Jack , Futreal P. Andrew , Zhang Jianhua , Reuben Alexandre , Tsao Anne S. , Zhang Jianjun
Published: April 2023

Supplementary Figure S1-10 and Table S1
Figure S3 from TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Authors: Rosen Ezra Y. , Goldman Debra A. , Hechtman Jaclyn F. , Benayed Ryma , Schram Alison M. , Cocco Emiliano , Shifman Sophie , Gong Yixiao , Kundra Ritika , Solomon James P. , Bardelli Alberto , Scaltriti Maurizio , Drilon Alexander , Iasonos Alexia , Taylor Barry S. , Hyman David M.
Published: April 2023

Supplemental Figure 3. Comparison of Tumor Types in Larotrectinib Study Population and MSK Cohort.
Figure S1 from TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations
Authors: Rosen Ezra Y. , Goldman Debra A. , Hechtman Jaclyn F. , Benayed Ryma , Schram Alison M. , Cocco Emiliano , Shifman Sophie , Gong Yixiao , Kundra Ritika , Solomon James P. , Bardelli Alberto , Scaltriti Maurizio , Drilon Alexander , Iasonos Alexia , Taylor Barry S. , Hyman David M.
Published: April 2023

Supplemental Figure 1. Venn Diagram of Patients in the Study.
Supplementary Materials from Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics
Authors: Topham James T. , Karasinska Joanna M. , Lee Michael K.C. , Csizmok Veronika , Williamson Laura M. , Jang Gun Ho , Denroche Robert E. , Tsang Erica S. , Kalloger Steve E. , Wong Hui-li , O'Kane Grainne M. , Moore Richard A. , Mungall Andrew J. , Notta Faiyaz , Loree Jonathan M. , Wilson Julie M. , Bathe Oliver , Tang Patricia A. , Goodwin Rachel , Knox Jennifer J. , Gallinger Steven , Laskin Janessa , Marra Marco A. , Jones Steven J.M. , Renouf Daniel J. , Schaeffer David F.
Published: April 2023

Supplementary Figures S1-7
Supplementary Fig. S3 from Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression
Authors: Tanimoto Azusa , Matsumoto Shingo , Takeuchi Shinji , Arai Sachiko , Fukuda Koji , Nishiyama Akihiro , Yoh Kiyotaka , Ikeda Takaya , Furuya Naoki , Nishino Kazumi , Ohe Yuichiro , Goto Koichi , Yano Seiji
Published: April 2023

Kaplan-Meier curves for PFS according to with and without loss-of-function mutations of TP53 in patients who received alectinib (A) or either of ALK-TKIs (alectinib, crizotinib, brigatinib, lorlatinib, ceritinib) (B) as the first TKI treatment.
Table S1 from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Authors: Tannir Nizar M. , Signoretti Sabina , Choueiri Toni K. , McDermott David F. , Motzer Robert J. , Flaifel Abdallah , Pignon Jean-Christophe , Ficial Miriam , Frontera Osvaldo Arén , George Saby , Powles Thomas , Donskov Frede , Harrison Michael R. , Barthélémy Philippe , Tykodi Scott S. , Kocsis Judit , Ravaud Alain , Rodriguez-Cid Jeronimo R. , Pal Sumanta K. , Murad Andre M. , Ishii Yuko , Saggi Shruti Shally , McHenry M. Brent , Rini Brian I.
Published: April 2023

ORR in patients with sRCC and I/P-risk disease, per IRRC, by central or local pathology review.
Figure S3 from Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Authors: Tannir Nizar M. , Signoretti Sabina , Choueiri Toni K. , McDermott David F. , Motzer Robert J. , Flaifel Abdallah , Pignon Jean-Christophe , Ficial Miriam , Frontera Osvaldo Arén , George Saby , Powles Thomas , Donskov Frede , Harrison Michael R. , Barthélémy Philippe , Tykodi Scott S. , Kocsis Judit , Ravaud Alain , Rodriguez-Cid Jeronimo R. , Pal Sumanta K. , Murad Andre M. , Ishii Yuko , Saggi Shruti Shally , McHenry M. Brent , Rini Brian I.
Published: April 2023

Overall survival (A) and progression-free survival (B) by baseline tumor PD-L1 expression (PD-L1 {greater than or equal to}1% and PD-L1 <1%) in patients with sRCC and I/P-risk disease.
Figure S3 from Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma
Authors: Spassova Ivelina , Ugurel Selma , Terheyden Patrick , Sucker Antje , Hassel Jessica C. , Ritter Cathrin , Kubat Linda , Habermann Daniel , Farahpour Farnoush , Saeedghalati Mohammadkarim , Peiffer Lukas , Kumar Rajiv , Schrama David , Hoffmann Daniel , Schadendorf Dirk , Becker Jürgen C.
Published: April 2023

Supplementary Figure S3. Higher prevalence of central memory T cells among TILs of responders.